BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11414524)

  • 21. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of the susceptibility of yeast isolates of clinical interest to five antifungal agents using the E test.
    Linares MJ; Muñoz JF; Solís F; Rodríguez FC; Valero A; Casal M
    Rev Esp Quimioter; 1998 Mar; 11(1):64-9. PubMed ID: 9795292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluconazole therapy in neonatal candidemia.
    Huang YC; Lin TY; Lien RI; Chou YH; Kuo CY; Yang PH; Hsieh WS
    Am J Perinatol; 2000; 17(8):411-5. PubMed ID: 11142391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.
    Pfaller MA; Diekema DJ; Sheehan DJ
    Clin Microbiol Rev; 2006 Apr; 19(2):435-47. PubMed ID: 16614256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.
    Nguyen MH; Clancy CJ; Yu VL; Yu YC; Morris AJ; Snydman DR; Sutton DA; Rinaldi MG
    J Infect Dis; 1998 Feb; 177(2):425-30. PubMed ID: 9466531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.
    Rex JH; Pfaller MA; Galgiani JN; Bartlett MS; Espinel-Ingroff A; Ghannoum MA; Lancaster M; Odds FC; Rinaldi MG; Walsh TJ; Barry AL
    Clin Infect Dis; 1997 Feb; 24(2):235-47. PubMed ID: 9114154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between in vitro and in vivo activity of antifungal agents against Candida species.
    Anaissie EJ; Karyotakis NC; Hachem R; Dignani MC; Rex JH; Paetznick V
    J Infect Dis; 1994 Aug; 170(2):384-9. PubMed ID: 8035024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical relevance of antifungal resistance.
    Espinel-Ingroff A
    Infect Dis Clin North Am; 1997 Dec; 11(4):929-44. PubMed ID: 9421708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis.
    Autmizguine J; Tan S; Cohen-Wolkowiez M; Cotten CM; Wiederhold N; Goldberg RN; Adams-Chapman I; Stoll BJ; Smith PB; Benjamin DK;
    Pediatr Infect Dis J; 2018 Sep; 37(9):923-929. PubMed ID: 29369937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia.
    Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 1999 May; 43(5):1289-90. PubMed ID: 10223955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis.
    Arthington-Skaggs BA; Warnock DW; Morrison CJ
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2081-5. PubMed ID: 10898679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia.
    Rodríguez-Tudela JL; Almirante B; Rodríguez-Pardo D; Laguna F; Donnelly JP; Mouton JW; Pahissa A; Cuenca-Estrella M
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3599-604. PubMed ID: 17646421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.
    Clancy CJ; Yu VL; Morris AJ; Snydman DR; Nguyen MH
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3171-7. PubMed ID: 16048920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is antifungal susceptibility testing useful in guiding fluconazole therapy?
    Ghannoum MA
    Clin Infect Dis; 1996 May; 22 Suppl 2():S161-5. PubMed ID: 8722845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.
    Lee SC; Fung CP; Huang JS; Tsai CJ; Chen KS; Chen HY; Lee N; See LC; Shieh WB
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2715-8. PubMed ID: 10991850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between susceptibility of Candida spp. isolates to amphotericin B and death or survival of patients with candidemia episodes.
    Alves SH; Boff E; Pozzatti P; Scheid LA; de Loreto E; Ottoneli Oliveira LT; Aquino V; Severo LC; Santurio JM
    Mycopathologia; 2009 Feb; 167(2):65-71. PubMed ID: 18819017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of antifungal MICs by a rapid susceptibility assay.
    Riesselman MH; Hazen KC; Cutler JE
    J Clin Microbiol; 2000 Jan; 38(1):333-40. PubMed ID: 10618111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of MICs of fluconazole and flucytosine when dissolved in dimethyl sulfoxide or water.
    Fothergill AW; Sanders C; Wiederhold NP
    J Clin Microbiol; 2013 Jun; 51(6):1955-7. PubMed ID: 23576540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Plasma and tissue concentrations of fluconazole: discussion of the breakpoint problem].
    Pittrow L; Penk A
    Mycoses; 1996; 39 Suppl 2():58-65. PubMed ID: 9198747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.